These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 31709742)

  • 1. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
    Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
    Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
    Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
    Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
    West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
    Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
    Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
    Park S; Kim JY; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Heo DS
    Korean J Intern Med; 2017 May; 32(3):514-522. PubMed ID: 28407465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
    Mellema WW; Masen-Poos L; Smit EF; Hendriks LE; Aerts JG; Termeer A; Goosens MJ; Smit HJ; van den Heuvel MM; van der Wekken AJ; Herder GJ; Krouwels FH; Stigt JA; van den Borne BE; Haitjema TJ; Staal-Van den Brekel AJ; van Heemst RC; Pouw E; Dingemans AM
    Lung Cancer; 2015 Nov; 90(2):249-54. PubMed ID: 26415993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
    Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
    Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
    Rulli E; Marabese M; Torri V; Farina G; Veronese S; Bettini A; Longo F; Moscetti L; Ganzinelli M; Lauricella C; Copreni E; Labianca R; Martelli O; Marsoni S; Broggini M; Garassino MC;
    Ann Oncol; 2015 Oct; 26(10):2079-84. PubMed ID: 26209642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
    Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
    Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
    [No Abstract]   [Full Text] [Related]  

  • 19. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
    Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
    Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
    Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.